

Sofie Struyf

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9363611/publications.pdf>

Version: 2024-02-01

165
papers

13,063
citations

19657

61
h-index

25787

108
g-index

165
all docs

165
docs citations

165
times ranked

16738
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of B Cell Depletion Therapy with Rituximab in Refractory Chronic Recurrent Uveitis Associated with Vogt-Koyanagi-Harada Disease. <i>Ocular Immunology and Inflammation</i> , 2022, 30, 750-757.	1.8	21
2	Inhibition of renal fibrosis with a human CXCL9-derived glycosaminoglycan-binding peptide. <i>Clinical and Translational Immunology</i> , 2022, 11, e1370.	3.8	2
3	Method Matters: Effect of Purification Technology on Neutrophil Phenotype and Function. <i>Frontiers in Immunology</i> , 2022, 13, 820058.	4.8	21
4	Affinity and Specificity for Binding to Glycosaminoglycans Can Be Tuned by Adapting Peptide Length and Sequence. <i>International Journal of Molecular Sciences</i> , 2022, 23, 447.	4.1	7
5	Citrullination as a novel posttranslational modification of matrix metalloproteinases. <i>Matrix Biology</i> , 2021, 95, 68-83.	3.6	21
6	Studying Neutrophil Function in vitro: Cell Models and Environmental Factors. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 141-162.	3.5	58
7	The turning away of serum amyloid A biological activities and receptor usage. <i>Immunology</i> , 2021, 163, 115-127.	4.4	16
8	Phenotypical and Functional Characterization of Neutrophils in Two Pyrin-Associated Auto-inflammatory Diseases. <i>Journal of Clinical Immunology</i> , 2021, 41, 1072-1084.	3.8	6
9	From ELISA to Immunosorbent Tandem Mass Spectrometry Proteoform Analysis: The Example of CXCL8/Interleukin-8. <i>Frontiers in Immunology</i> , 2021, 12, 644725.	4.8	8
10	The Antimicrobial Activity of Peripheral Blood Neutrophils Is Altered in Patients with Primary Ciliary Dyskinesia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6172.	4.1	6
11	The Role of Post-Translational Modifications of Chemokines by CD26 in Cancer. <i>Cancers</i> , 2021, 13, 4247.	3.7	8
12	Kinetics of peripheral blood neutrophils in severe coronavirus disease 2019. <i>Clinical and Translational Immunology</i> , 2021, 10, e1271.	3.8	36
13	The Chemokine-Based Peptide, CXCL9(74-103), Inhibits Angiogenesis by Blocking Heparan Sulfate Proteoglycan-Mediated Signaling of Multiple Endothelial Growth Factors. <i>Cancers</i> , 2021, 13, 5090.	3.7	12
14	New Perspectives on the Immunopathogenesis and Treatment of Uveitis Associated With Vogt-Koyanagi-Harada Disease. <i>Frontiers in Medicine</i> , 2021, 8, 705796.	2.6	17
15	Tissue Inhibitor of Metalloproteinase-3 Ameliorates Diabetes-Induced Retinal Inflammation. <i>Frontiers in Physiology</i> , 2021, 12, 807747.	2.8	8
16	Local Cytokine Expression Profiling in Patients with Specific Autoimmune Uveitic Entities. <i>Ocular Immunology and Inflammation</i> , 2020, 28, 453-462.	1.8	24
17	Soluble cytokine receptor levels in aqueous humour of patients with specific autoimmune uveitic entities: sCD30 is a biomarker of granulomatous uveitis. <i>Eye</i> , 2020, 34, 1614-1623.	2.1	8
18	Biological Characterization of Commercial Recombinantly Expressed Immunomodulating Proteins Contaminated with Bacterial Products in the Year 2020: The SAA3 Case. <i>Mediators of Inflammation</i> , 2020, 2020, 1-17.	3.0	3

#	ARTICLE	IF	CITATIONS
19	CXCL14 Preferentially Synergizes With Homeostatic Chemokine Receptor Systems. <i>Frontiers in Immunology</i> , 2020, 11, 561404.	4.8	20
20	Serum Amyloid A1 (SAA1) Revisited: Restricted Leukocyte-Activating Properties of Homogeneous SAA1. <i>Frontiers in Immunology</i> , 2020, 11, 843.	4.8	31
21	Neutrophils: Underestimated Players in the Pathogenesis of Multiple Sclerosis (MS). <i>International Journal of Molecular Sciences</i> , 2020, 21, 4558.	4.1	58
22	Induction of Chemokines by Hepatitis C Virus Proteins: Synergy of the Core Protein with Interleukin-1 β and Interferon- γ in Liver Bystander Cells. <i>Journal of Interferon and Cytokine Research</i> , 2020, 40, 195-206.	1.2	5
23	Evaluation of Proteoforms of the Transmembrane Chemokines CXCL16 and CX3CL1, Their Receptors, and Their Processing Metalloproteinases ADAM10 and ADAM17 in Proliferative Diabetic Retinopathy. <i>Frontiers in Immunology</i> , 2020, 11, 601639.	4.8	25
24	The ectoenzyme-side of matrix metalloproteinases (MMPs) makes inflammation by serum amyloid A (SAA) and chemokines go round. <i>Immunology Letters</i> , 2019, 205, 1-8.	2.5	11
25	Cytokines and serum amyloid A in the pathogenesis of hepatitis C virus infection. <i>Cytokine and Growth Factor Reviews</i> , 2019, 50, 29-42.	7.2	20
26	Human DOCK2 Deficiency: Report of a Novel Mutation and Evidence for Neutrophil Dysfunction. <i>Journal of Clinical Immunology</i> , 2019, 39, 298-308.	3.8	31
27	Expression of interleukin (<sc>IL</sc>)â€10 family cytokines in aqueous humour of patients with specific endogenous uveitic entities: elevated levels of <sc>IL</sc>â€19 in human leucocyte antigenâ€B27â€associated uveitis. <i>Acta Ophthalmologica</i> , 2019, 97, e780-e784.	1.1	16
28	The Proinflammatory and Proangiogenic Macrophage Migration Inhibitory Factor Is a Potential Regulator in Proliferative Diabetic Retinopathy. <i>Frontiers in Immunology</i> , 2019, 10, 2752.	4.8	50
29	The <sc>CC</sc> chemokines <sc>CCL</sc>8, <sc>CCL</sc>13 and <sc>CCL</sc>20 are local inflammatory biomarkers of <sc>HLA</sc>â€B27â€associated uveitis. <i>Acta Ophthalmologica</i> , 2019, 97, e122-e128.	1.1	22
30	Reduction of myeloid-derived suppressor cells reinforces the anti-solid tumor effect of recipient leukocyte infusion in murine neuroblastoma-bearing allogeneic bone marrow chimeras. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 589-603.	4.2	10
31	The unique structural and functional features of CXCL12. <i>Cellular and Molecular Immunology</i> , 2018, 15, 299-311.	10.5	243
32	Chemoattractants and cytokines in primary ciliary dyskinesia and cystic fibrosis: key players in chronic respiratory diseases. <i>Cellular and Molecular Immunology</i> , 2018, 15, 312-323.	10.5	27
33	Peroxynitrite Exposure of CXCL12 Impairs Monocyte, Lymphocyte and Endothelial Cell Chemotaxis, Lymphocyte Extravasation in vivo and Anti-HIV-1 Activity. <i>Frontiers in Immunology</i> , 2018, 9, 1933.	4.8	5
34	Chemokine-Induced Macrophage Polarization in Inflammatory Conditions. <i>Frontiers in Immunology</i> , 2018, 9, 1930.	4.8	266
35	Pathological roles of the homeostatic chemokine CXCL12. <i>Cytokine and Growth Factor Reviews</i> , 2018, 44, 51-68.	7.2	110
36	Matrix Metalloproteinase-9-Generated COOH-, but Not NH ₂ -Terminal Fragments of Serum Amyloid A1 Retain Potentiating Activity in Neutrophil Migration to CXCL8, With Loss of Direct Chemotactic and Cytokine-Inducing Capacity. <i>Frontiers in Immunology</i> , 2018, 9, 1081.	4.8	15

#	ARTICLE	IF	CITATIONS
37	Anti-inflammatory effects of the GAG-binding CXCL9(74-103) peptide in dinitrofluorobenzene-induced contact hypersensitivity in mice. <i>Clinical and Experimental Allergy</i> , 2018, 48, 1333-1344.	2.9	9
38	Differential CXC and CX3C Chemokine Expression Profiles in Aqueous Humor of Patients With Specific Endogenous Uveitic Entities. , 2018, 59, 2222.		40
39	CXCL4 and CXCL4L1 in cancer. <i>Cytokine</i> , 2018, 109, 65-71.	3.2	25
40	How post-translational modifications influence the biological activity of chemokines. <i>Cytokine</i> , 2018, 109, 29-51.	3.2	44
41	COOH-terminal SAA1 peptides fail to induce chemokines but synergize with CXCL8 and CCL3 to recruit leukocytes via FPR2. <i>Blood</i> , 2018, 131, 439-449.	1.4	17
42	Recombinant Parvoviruses Armed to Deliver CXCL4L1 and CXCL10 Are Impaired in Their Antiangiogenic and Antitumoral Effects in a Kaposi Sarcoma Tumor Model Due To the Chemokines' Interference with the Virus Cycle. <i>Human Gene Therapy</i> , 2017, 28, 295-306.	2.7	8
43	Truncation of CXCL12 by CD26 reduces its CXC chemokine receptor 4- and atypical chemokine receptor 3-dependent activity on endothelial cells and lymphocytes. <i>Biochemical Pharmacology</i> , 2017, 132, 92-101.	4.4	42
44	Relative distribution and biological characterization of CXCL4L1 isoforms in platelets from healthy donors. <i>Biochemical Pharmacology</i> , 2017, 145, 123-131.	4.4	4
45	Tumor angiogenesis revisited: Regulators and clinical implications. <i>Medicinal Research Reviews</i> , 2017, 37, 1231-1274.	10.5	138
46	Chemokine isoforms and processing in inflammation and immunity. <i>Journal of Autoimmunity</i> , 2017, 85, 45-57.	6.5	67
47	CXCL9-Derived Peptides Differentially Inhibit Neutrophil Migration In Vivo through Interference with Glycosaminoglycan Interactions. <i>Frontiers in Immunology</i> , 2017, 8, 530.	4.8	33
48	Neutrophils from Patients with Primary Ciliary Dyskinesia Display Reduced Chemotaxis to CXCR2 Ligands. <i>Frontiers in Immunology</i> , 2017, 8, 1126.	4.8	12
49	Osteoprotegerin Is a New Regulator of Inflammation and Angiogenesis in Proliferative Diabetic Retinopathy. , 2017, 58, 3189.		30
50	Overview of the Mechanisms that May Contribute to the Non-Redundant Activities of Interferon-Inducible CXC Chemokine Receptor 3 Ligands. <i>Frontiers in Immunology</i> , 2017, 8, 1970.	4.8	227
51	Structure and Expression of Different Serum Amyloid A (SAA) Variants and their Concentration-Dependent Functions During Host Insults. <i>Current Medicinal Chemistry</i> , 2016, 23, 1725-1755.	2.4	180
52	The Cytokine Interleukin-6 and the Chemokines CCL20 and CXCL13 Are Novel Biomarkers of Specific Endogenous Uveitic Entities. , 2016, 57, 4606.		36
53	Transforming Growth Factor Beta Switch in Aqueous Humor of Patients With Fuchs' Endothelial Corneal Dystrophy. , 2016, 57, 771.		12
54	The cytokine-serum amyloid A-chemokine network. <i>Cytokine and Growth Factor Reviews</i> , 2016, 30, 55-69.	7.2	99

#	ARTICLE	IF	CITATIONS
55	CD26/dipeptidylpeptidase IV chemokine interactions: double-edged regulation of inflammation and tumor biology. <i>Journal of Leukocyte Biology</i> , 2016, 99, 955-969.	3.3	75
56	CXCL4 and CXCL4L1 Differentially Affect Monocyte Survival and Dendritic Cell Differentiation and Phagocytosis. <i>PLoS ONE</i> , 2016, 11, e0166006.	2.5	39
57	Natural nitration of CXCL12 reduces its signaling capacity and chemotactic activity <i>in vitro</i> and abrogates intra-articular lymphocyte recruitment <i>in vivo</i> . <i>Oncotarget</i> , 2016, 7, 62439-62459.	1.8	32
58	Myofibroblasts in proliferative diabetic retinopathy can originate from infiltrating fibrocytes and through endothelial-to-mesenchymal transition (EndoMT). <i>Experimental Eye Research</i> , 2015, 132, 179-189.	2.6	76
59	The Chemokine Platelet Factor-4 Variant (PF-4var)/CXCL4L1 Inhibits Diabetes-Induced Blood Retinal Barrier Breakdown. , 2015, 56, 1956.		14
60	Serum amyloid A β induces paracrine IL-8/CXCL8 via TLR2 and directly synergizes with this chemokine via CXCR2 and formyl peptide receptor 2 to recruit neutrophils. <i>Journal of Leukocyte Biology</i> , 2015, 98, 1049-1060.	3.3	40
61	Serum amyloid A chemoattracts immature dendritic cells and indirectly provokes monocyte chemotaxis by induction of cooperating CC and CXC chemokines. <i>European Journal of Immunology</i> , 2015, 45, 101-112.	2.9	57
62	CXCR3 ligands in disease and therapy. <i>Cytokine and Growth Factor Reviews</i> , 2015, 26, 311-327.	7.2	239
63	CXCL4L1 and CXCL4 signaling in human lymphatic and microvascular endothelial cells and activated lymphocytes: involvement of mitogen-activated protein (MAP) kinases, Src and p70S6 kinase. <i>Angiogenesis</i> , 2014, 17, 631-640.	7.2	19
64	Chemokines and other GPCR ligands synergize in receptor-mediated migration of monocyte-derived immature and mature dendritic cells. <i>Immunobiology</i> , 2014, 219, 218-229.	1.9	63
65	Angiostatic, tumor inflammatory and anti-tumor effects of CXCL447-70 and CXCL4L147-70 in an EGF-dependent breast cancer model. <i>Oncotarget</i> , 2014, 5, 10916-10933.	1.8	23
66	Pathogenesis of malaria-associated acute respiratory distress syndrome. <i>Trends in Parasitology</i> , 2013, 29, 346-358.	3.3	79
67	Capacity of wild-type and chemokine-armed parvovirus H-1PV for inhibiting neo-angiogenesis. <i>Virology</i> , 2013, 447, 221-232.	2.4	11
68	Autocrine CCL2, CXCL4, CXCL9 and CXCL10 signal in retinal endothelial cells and are enhanced in diabetic retinopathy. <i>Experimental Eye Research</i> , 2013, 109, 67-76.	2.6	74
69	Identification and characterization of MIP-1 β /CCL3 isoform 2 from bovine serum as a potent monocyte/dendritic cell chemoattractant. <i>Biochemical Pharmacology</i> , 2013, 85, 789-797.	4.4	14
70	CXCL6 antibody neutralization prevents lung inflammation and fibrosis in mice in the bleomycin model. <i>Journal of Leukocyte Biology</i> , 2013, 94, 1317-1323.	3.3	51
71	Neurotrophins and Neurotrophin Receptors in Proliferative Diabetic Retinopathy. <i>PLoS ONE</i> , 2013, 8, e65472.	2.5	36
72	Antitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: implication of leucocyte recruitment. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 2113-2123.	4.2	46

#	ARTICLE	IF	CITATIONS
73	Possible mechanisms involved in chemokine synergy fine tuning the inflammatory response. <i>Immunology Letters</i> , 2012, 145, 10-14.	2.5	52
74	Cytokine and CXC chemokine expression patterns in aqueous humor of patients with presumed tuberculous uveitis. <i>Cytokine</i> , 2012, 59, 377-381.	3.2	31
75	The role of CXC chemokines in the transition of chronic inflammation to esophageal and gastric cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2012, 1825, 117-129.	7.4	95
76	PF-4var/CXCL4L1 Predicts Outcome in Stable Coronary Artery Disease Patients with Preserved Left Ventricular Function. <i>PLoS ONE</i> , 2012, 7, e31343.	2.5	19
77	PS2-046. New developments in mouse cytokine auto-vaccination with particular emphasis on anti-GCP-2/CXCL6. <i>Cytokine</i> , 2011, 56, 75.	3.2	0
78	The role of the CXC chemokines platelet factor-4 (CXCL4/PF-4) and its variant (CXCL4L1/PF-4var) in inflammation, angiogenesis and cancer. <i>Cytokine and Growth Factor Reviews</i> , 2011, 22, 1-18.	7.2	136
79	The expression and role of CXC chemokines in colorectal cancer. <i>Cytokine and Growth Factor Reviews</i> , 2011, 22, 345-358.	7.2	114
80	Isotypic neutralizing antibodies against mouse GCP-2/CXCL6 inhibit melanoma growth and metastasis. <i>Cancer Letters</i> , 2011, 302, 54-62.	7.2	52
81	Circulating bone marrow-derived endothelial precursor cells contribute to neovascularization in diabetic epiretinal membranes. <i>Acta Ophthalmologica</i> , 2011, 89, 222-228.	1.1	40
82	CXC chemokine expression profiles in aqueous humor of patients with different clinical entities of endogenous uveitis. <i>Immunobiology</i> , 2011, 216, 1004-1009.	1.9	46
83	Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3. <i>Blood</i> , 2011, 117, 480-488.	1.4	95
84	Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis. <i>Clinical Immunology</i> , 2011, 139, 177-184.	3.2	125
85	Longitudinal changes in gingival crevicular fluid after placement of fixed orthodontic appliances. <i>American Journal of Orthodontics and Dentofacial Orthopedics</i> , 2011, 139, 735-744.	1.7	38
86	CXCR4 and CCR5 ligands cooperate in monocyte and lymphocyte migration and in inhibition of dual-tropic (R5/X4) HIV-1 infection. <i>European Journal of Immunology</i> , 2011, 41, 963-973.	2.9	64
87	Amine-reactive OVA multimers for auto-vaccination against cytokines and other mediators: perspectives illustrated for GCP-2 in <i>L. major</i> infection. <i>Journal of Leukocyte Biology</i> , 2011, 89, 1001-1007.	3.3	29
88	Langerhans cell histiocytosis: a cytokine/chemokine-mediated disorder?. <i>European Cytokine Network</i> , 2011, 22, 148-153.	2.0	21
89	The COOH-Terminal Peptide of Platelet Factor-4 Variant (CXCL4L1/PF-4var47-70) Strongly Inhibits Angiogenesis and Suppresses B16 Melanoma Growth <i>in vivo</i> . <i>Molecular Cancer Research</i> , 2010, 8, 322-334.	3.4	41
90	Expression of angiostatic platelet factor-4var/CXCL4L1 counterbalances angiogenic impulses of vascular endothelial growth factor, interleukin-8/CXCL8, and stromal cell-derived factor 1/CXCL12 in esophageal and colorectal cancer. <i>Human Pathology</i> , 2010, 41, 990-1001.	2.0	22

#	ARTICLE	IF	CITATIONS
91	Expression of stem cell factor/c-kit signaling pathway components in diabetic fibrovascular epiretinal membranes. <i>Molecular Vision</i> , 2010, 16, 1098-107.	1.1	34
92	Citrullination of CXCL12 Differentially Reduces CXCR4 and CXCR7 Binding with Loss of Inflammatory and Anti-HIV-1 Activity via CXCR4. <i>Journal of Immunology</i> , 2009, 182, 666-674.	0.8	86
93	Recognition Versus Adaptive Up-regulation and Degradation of CC Chemokines by the Chemokine Decoy Receptor D6 Are Determined by Their N-terminal Sequence. <i>Journal of Biological Chemistry</i> , 2009, 284, 26207-26215.	3.4	49
94	CC chemokine ligand-2 synergizes with the nonchemokine G protein-coupled receptor ligand fMLP in monocyte chemotaxis, and it cooperates with the TLR ligand LPS via induction of CXCL8. <i>Journal of Leukocyte Biology</i> , 2009, 86, 671-680.	3.3	21
95	Contribution of intracellular Ca ²⁺ stores to Ca ²⁺ signaling during chemokinesis of human neutrophil granulocytes. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2009, 1793, 1041-1049.	4.1	15
96	Synergistic up-regulation of MCP-2/CCL8 activity is counteracted by chemokine cleavage, limiting its inflammatory and anti-tumoral effects. <i>European Journal of Immunology</i> , 2009, 39, 843-857.	2.9	57
97	Carcinoma cell-derived chemokines and their presence in oral fluid. <i>European Journal of Oral Sciences</i> , 2009, 117, 362-368.	1.5	30
98	Interleukin-17 regulates chemokine and gelatinase B expression in fibroblasts to recruit both neutrophils and monocytes. <i>Immunobiology</i> , 2009, 214, 835-842.	1.9	44
99	CXCR3 determines strain susceptibility to murine cerebral malaria by mediating lymphocyte migration toward IFN- β -induced chemokines. <i>European Journal of Immunology</i> , 2008, 38, 1082-1095.	2.9	97
100	The role of CXC chemokines and their receptors in cancer. <i>Cancer Letters</i> , 2008, 267, 226-244.	7.2	565
101	Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation. <i>Journal of Experimental Medicine</i> , 2008, 205, 2085-2097.	8.5	159
102	Synergy between Coproduced CC and CXC Chemokines in Monocyte Chemotaxis through Receptor-Mediated Events. <i>Molecular Pharmacology</i> , 2008, 74, 485-495.	2.3	108
103	Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation. <i>Journal of Cell Biology</i> , 2008, 182, i9-i9.	5.2	0
104	Platelet Factor-4 Variant Chemokine CXCL4L1 Inhibits Melanoma and Lung Carcinoma Growth and Metastasis by Preventing Angiogenesis. <i>Cancer Research</i> , 2007, 67, 5940-5948.	0.9	106
105	Stimulation of angiostatic platelet factor-4 variant (CXCL4L1/PF-4var) versus inhibition of angiogenic granulocyte chemotactic protein-2 (CXCL6/GCP-2) in normal and tumoral mesenchymal cells. <i>Journal of Leukocyte Biology</i> , 2007, 82, 1519-1530.	3.3	32
106	Protective role of IFN- β in collagen-induced arthritis conferred by inhibition of mycobacteria-induced granulocyte chemotactic protein-2 production. <i>Journal of Leukocyte Biology</i> , 2007, 81, 1044-1053.	3.3	41
107	Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration. <i>Blood</i> , 2007, 110, 37-44.	1.4	115
108	MCP-3 (CCL7) delivered by parvovirus MVMp reduces tumorigenicity of mouse melanoma cells through activation of T lymphocytes and NK cells. <i>International Journal of Cancer</i> , 2007, 120, 1364-1371.	5.1	43

#	ARTICLE	IF	CITATIONS
109	The role of chemokines and their receptors in uveitis. <i>International Ophthalmology</i> , 2007, 27, 321-327.	1.4	5
110	Coexpression and interaction of CXCL10 and CD26 in mesenchymal cells by synergising inflammatory cytokines: CXCL8 and CXCL10 are discriminative markers for autoimmune arthropathies. <i>Arthritis Research and Therapy</i> , 2006, 8, R107.	3.5	57
111	The activated form of gelatinase B/matrix metalloproteinase-9 is associated with diabetic vitreous hemorrhage. <i>Experimental Eye Research</i> , 2006, 83, 401-407.	2.6	46
112	TLR ligands and cytokines induce CXCR3 ligands in endothelial cells: enhanced CXCL9 in autoimmune arthritis. <i>Laboratory Investigation</i> , 2006, 86, 902-916.	3.7	92
113	Structure/Function Relationships of CCR8 Agonists and Antagonists. <i>Journal of Biological Chemistry</i> , 2006, 281, 36652-36661.	3.4	30
114	Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. <i>European Cytokine Network</i> , 2006, 17, 155-65.	2.0	113
115	Chemokines synergize in the recruitment of circulating neutrophils into inflamed tissue. <i>European Journal of Immunology</i> , 2005, 35, 1583-1591.	2.9	84
116	GCP-2/CXCL6 synergizes with other endothelial cell-derived chemokines in neutrophil mobilization and is associated with angiogenesis in gastrointestinal tumors. <i>Experimental Cell Research</i> , 2005, 303, 331-342.	2.6	141
117	Synergy in cytokine and chemokine networks amplifies the inflammatory response. <i>Cytokine and Growth Factor Reviews</i> , 2005, 16, 561-580.	7.2	184
118	Synergy between proinflammatory ligands of G protein-coupled receptors in neutrophil activation and migration. <i>Journal of Leukocyte Biology</i> , 2004, 76, 185-194.	3.3	102
119	Platelets Release CXCL4L1, a Nonallelic Variant of the Chemokine Platelet Factor-4/CXCL4 and Potent Inhibitor of Angiogenesis. <i>Circulation Research</i> , 2004, 95, 855-857.	4.5	151
120	Synergistic induction of CXCL9 and CXCL11 by Toll-like receptor ligands and interferon- γ in fibroblasts correlates with elevated levels of CXCR3 ligands in septic arthritis synovial fluids. <i>Journal of Leukocyte Biology</i> , 2004, 75, 777-784.	3.3	81
121	Chemokine-protease interactions in cancer. <i>Seminars in Cancer Biology</i> , 2004, 14, 201-208.	9.6	65
122	Rabbit neutrophil chemotactic protein (NCP) activates both CXCR1 and CXCR2 and is the functional homologue for human CXCL6. <i>Biochemical Pharmacology</i> , 2004, 68, 1947-1955.	4.4	5
123	CXCR1-binding chemokines in inflammatory bowel diseases: down-regulated IL-8/CXCL8 production by leukocytes in Crohn's disease and selective GCP-2/CXCL6 expression in inflamed intestinal tissue. <i>European Journal of Immunology</i> , 2004, 34, 1992-2000.	2.9	67
124	Chemokines and gelatinases in the aqueous humor of patients with active uveitis. <i>American Journal of Ophthalmology</i> , 2004, 138, 401-411.	3.3	50
125	CCR8-dependent activation of the RAS/MAPK pathway mediates anti-apoptotic activity of I-309/CCL1 and vMIP-I. <i>European Journal of Immunology</i> , 2003, 33, 494-501.	2.9	56
126	Microbial Toll-like receptor ligands differentially regulate CXCL10/IP-10 expression in fibroblasts and mononuclear leukocytes in synergy with IFN- γ and provide a mechanism for enhanced synovial chemokine levels in septic arthritis. <i>European Journal of Immunology</i> , 2003, 33, 3146-3153.	2.9	96

#	ARTICLE	IF	CITATIONS
127	The CXC Chemokine GCP-2/CXCL6 Is Predominantly Induced in Mesenchymal Cells by Interleukin-1 β and Is Down-Regulated by Interferon- γ : Comparison with Interleukin-8/CXCL8. <i>Laboratory Investigation</i> , 2003, 83, 23-34.	3.7	83
128	The T-lymphocyte chemoattractant Mig is highly expressed in vernal keratoconjunctivitis. <i>American Journal of Ophthalmology</i> , 2003, 136, 853-860.	3.3	21
129	PARC/CCL18 Is a Plasma CC Chemokine with Increased Levels in Childhood Acute Lymphoblastic Leukemia. <i>American Journal of Pathology</i> , 2003, 163, 2065-2075.	3.8	72
130	The CC chemokine CCL20 and its receptor CCR6. <i>Cytokine and Growth Factor Reviews</i> , 2003, 14, 409-426.	7.2	660
131	Regulation of the Immune Response by the Interaction of Chemokines and Proteases. <i>Advances in Immunology</i> , 2003, 81, 1-44.	2.2	102
132	Unique Regulation of CCL18 Production by Maturing Dendritic Cells. <i>Journal of Immunology</i> , 2003, 170, 3843-3849.	0.8	144
133	Functional Characterization of Human Receptors for Short Chain Fatty Acids and Their Role in Polymorphonuclear Cell Activation. <i>Journal of Biological Chemistry</i> , 2003, 278, 25481-25489.	3.4	1,286
134	Role of Chemokines in Vernal Keratoconjunctivitis. <i>International Ophthalmology Clinics</i> , 2003, 43, 33-39.	0.7	14
135	Natural Substrates of Dipeptidyl Peptidase IV. <i>Advances in Experimental Medicine and Biology</i> , 2002, 477, 67-87.	1.6	71
136	The Unique Property of the CC Chemokine Regakine-1 to Synergize with Other Plasma-Derived Inflammatory Mediators in Neutrophil Chemotaxis Does Not Reside in Its NH ₂ -Terminal Structure. <i>Molecular Pharmacology</i> , 2002, 62, 173-180.	2.3	25
137	Identification of Biologically Active Chemokine Isoforms from Ascitic Fluid and Elevated Levels of CCL18/Pulmonary and Activation-regulated Chemokine in Ovarian Carcinoma. <i>Journal of Biological Chemistry</i> , 2002, 277, 24584-24593.	3.4	193
138	Role of the autocrine chemokines MIP-1 α and MIP-1 β in the metastatic behavior of murine T cell lymphoma. <i>Journal of Leukocyte Biology</i> , 2002, 72, 780-9.	3.3	22
139	Gene Cloning of a New Plasma CC Chemokine, Activating and Attracting Myeloid Cells in Synergy with Other Chemoattractants. <i>Biochemistry</i> , 2001, 40, 11715-11722.	2.5	15
140	Identification of a blood-derived chemoattractant for neutrophils and lymphocytes as a novel CC chemokine, Regakine-1. <i>Blood</i> , 2001, 97, 2197-2204.	1.4	41
141	Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. <i>Blood</i> , 2001, 98, 3554-3561.	1.4	227
142	Dendritic cells as a major source of macrophage-derived chemokine/CCL22 in vitro and in vivo. <i>European Journal of Immunology</i> , 2001, 31, 812-822.	2.9	246
143	Diverging binding capacities of natural LD78 isoforms of macrophage inflammatory protein-1 α to the CC chemokine receptors 1, 3 and 5 affect their anti-HIV-1 activity and chemotactic potencies for neutrophils and eosinophils. <i>European Journal of Immunology</i> , 2001, 31, 2170-2178.	2.9	91
144	Selective induction of CCL18/PARC by staphylococcal enterotoxins in mononuclear cells and enhanced levels in septic and rheumatoid arthritis. <i>European Journal of Immunology</i> , 2001, 31, 3755-3762.	2.9	51

#	ARTICLE	IF	CITATIONS
145	The LD78 ¹ Isoform of MIP-1 ¹ Is the Most Potent CC-Chemokine in Inhibiting CCR5-Dependent Human Immunodeficiency Virus Type 1 Replication in Human Macrophages. <i>Journal of Virology</i> , 2001, 75, 4402-4406.	3.4	50
146	Selective induction of CCL18/PARC by staphylococcal enterotoxins in mononuclear cells and enhanced levels in septic and rheumatoid arthritis. , 2001, 31, 3755.		1
147	Cleavage by CD26/dipeptidyl peptidase IV converts the chemokine LD78 ¹ into a most efficient monocyte attractant and CCR1 agonist. <i>Blood</i> , 2000, 96, 1674-1680.	1.4	151
148	Regulated Production and Molecular Diversity of Human Liver and Activation-Regulated Chemokine/Macrophage Inflammatory Protein-3 ¹ from Normal and Transformed Cells. <i>Journal of Immunology</i> , 2000, 165, 4470-4477.	0.8	76
149	Biochemical and Biological Characterization of Neutrophil Chemotactic Protein, a Novel Rabbit CXC Chemokine from Alveolar Macrophages. <i>Biochemistry</i> , 2000, 39, 14549-14557.	2.5	10
150	Cleavage by CD26/dipeptidyl peptidase IV converts the chemokine LD78 ¹ into a most efficient monocyte attractant and CCR1 agonist. <i>Blood</i> , 2000, 96, 1674-1680.	1.4	4
151	Activity of Different Bicyclam Derivatives against Human Immunodeficiency Virus Depends on Their Interaction with the CXCR4 Chemokine Receptor. <i>Molecular Pharmacology</i> , 1999, 55, 67-73.	2.3	107
152	cis Requirements for the Efficient Production of Recombinant DNA Vectors Based on Autonomous Parvoviruses. <i>Human Gene Therapy</i> , 1999, 10, 1619-1632.	2.7	84
153	Truncation of Macrophage-derived Chemokine by CD26/ Dipeptidyl-Peptidase IV beyond Its Predicted Cleavage Site Affects Chemotactic Activity and CC Chemokine Receptor 4 Interaction. <i>Journal of Biological Chemistry</i> , 1999, 274, 3988-3993.	3.4	142
154	Isolation of the CXC chemokines ENA-78, GRO ¹ and GRO ³ from tumor cells and leukocytes reveals NH2-terminal heterogeneity. <i>FEBS Journal</i> , 1999, 260, 421-429.	0.2	75
155	Differential induction of monocyte chemotactic protein-3 in mononuclear leukocytes and fibroblasts by interferon- ¹ and interferon- ³ reveals MCP-3 heterogeneity. <i>European Journal of Immunology</i> , 1999, 29, 678-685.		63
156	Synthesis and Structure~Activity Relationships of Phenylenebis(methylene)- Linked Bis-azamacrocycles That Inhibit HIV-1 and HIV-2 Replication by Antagonism of the Chemokine Receptor CXCR4. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 3971-3981.	6.4	107
157	The LD78 ¹ isoform of MIP-1 ¹ is the most potent CCR5 agonist and HIV-1~inhibiting chemokine. <i>Journal of Clinical Investigation</i> , 1999, 104, R1-R5.	8.2	93
158	CD26-processed RANTES(3~68), but not intact RANTES, has potent anti-HIV-1 activity. <i>Antiviral Research</i> , 1998, 39, 175-187.	4.1	75
159	Natural truncation of RANTES abolishes signaling through the CC chemokine receptors CCR1 and CCR3, impairs its chemotactic potency and generates a CC chemokine inhibitor. <i>European Journal of Immunology</i> , 1998, 28, 1262-1271.	2.9	130
160	Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1 ¹ . <i>FEBS Letters</i> , 1998, 432, 73-76.	2.8	187
161	Functional Comparison of Two Human Monocyte Chemotactic Protein-2 Isoforms, Role of the Amino-Terminal Pyroglutamic Acid and Processing by CD26/Dipeptidyl Peptidase IV. <i>Biochemistry</i> , 1998, 37, 12672-12680.	2.5	141
162	Amino-terminal Truncation of Chemokines by CD26/Dipeptidyl-peptidase IV. <i>Journal of Biological Chemistry</i> , 1998, 273, 7222-7227.	3.4	238

#	ARTICLE	IF	CITATIONS
163	Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4. Journal of Experimental Medicine, 1997, 186, 1383-1388.	8.5	559
164	Granulocyte chemotactic protein-2 and related CXC chemokines: from gene regulation to receptor usage. Journal of Leukocyte Biology, 1997, 62, 563-569.	3.3	98
165	Isolation of human monocyte chemotactic proteins and study of their producer and responder cells by immunotests and bioassays. Methods in Enzymology, 1997, 287, 109-127.	1.0	3